睿知中国医院研究地图
候选清单

正在招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由厦门大学附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06158386,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:仅女性

    登记记录的入选字段

  2. The patients diagnosed with follicular lymphoma with grade 1-3a, have received at least second-line systemic treatment, and at least one of the first-line treatments includes anti-CD20 monoclonal antibody (anti-CD20 monoclonal antibody monotherapy or combined chemotherapy). If the latest histopathological diagnosis is more than 6 months, a lymph node or tissue puncture or biopsy (resection or coarse needle puncture) must be performed.

    入选标准第 1 条

  3. Received systemic anti-tumor therapy or radiotherapy within 4 weeks before enrollment.

    排除标准第 11 条

    The patients received the transplantation of somatic hematopoietic stem cells within 3 months before enrollment.

    排除标准第 13 条

    Patients received allogeneic hematopoietic stem cell transplantation or had any active graft-versus-host disease within 6 months before drug administration.

    排除标准第 14 条

    Before the first drug administration, the toxic reaction of previous anti-tumor therapy has not recovered to ≤1 level (except alopecia).

    排除标准第 16 条

  4. ECOG ≤ 2.

    入选标准第 4 条

  5. Impaired bone marrow function: neutrophils < 1.5× 10*9/L, HB < 80 g/L, PLT < 75×10*9 /L, Impaired liver function, defined as serum total bilirubin > 1.5 x ULN or serum ALT and AST > 2.5x ULN, Patients with liver infiltration by lymphoma, AST and ALT > 5x ULN, Renal glomerular filtration rate (eGFR) < 30 ml/min.

    排除标准第 3 条

    PT INR>1.5ULN or APTT> 1.5 ULN, Serum amylase or lipase > 1ULN.

    排除标准第 4 条

  6. The patients have at least one measurable lesion (any length of lymph node lesion > 1.5cm or any length of extranodal lesion > 1 cm) examined by computed tomography (CT)/ magnetic resonance imaging (MRI).

    入选标准第 6 条

  7. Patients with active infection of the human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV), if patients with HBV infection with HBsAg or hepatitis B core antibody (HBcAb) positive] but HBV DNA negative can be included, However, these patients need continuous antiviral treatment and HBV DNA PCR detection every cycle after enrollment.

    排除标准第 5 条

  8. Pregnant (serum pregnancy test results are positive) or lactating women

    排除标准第 20 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06158386,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. The patients diagnosed with follicular lymphoma with grade 1-3a, have received at least second-line systemic treatment, and at least one of the first-line treatments includes anti-CD20 monoclonal antibody (anti-CD20 monoclonal antibody monotherapy or combined chemotherapy). If the latest histopathological diagnosis is more than 6 months, a lymph node or tissue puncture or biopsy (resection or coarse needle puncture) must be performed.
  2. Age ≥18 years old, regardless of gender.
  3. The estimated survival time is more than 3 months.
  4. ECOG ≤ 2.
  5. Be able to follow the requirements of the research plan.
  6. The patients have at least one measurable lesion (any length of lymph node lesion > 1.5cm or any length of extranodal lesion > 1 cm) examined by computed tomography (CT)/ magnetic resonance imaging (MRI).
  7. Be able to understand and voluntarily provide informed consent.

排除标准:Exclusion Criteria:

  1. CNS involvement (current or previous).
  2. Clinical evidence of transformation to a more aggressive subtype of lymphoma
  3. Impaired bone marrow function: neutrophils < 1.5× 10*9/L, HB < 80 g/L, PLT < 75×10*9 /L, Impaired liver function, defined as serum total bilirubin > 1.5 x ULN or serum ALT and AST > 2.5x ULN, Patients with liver infiltration by lymphoma, AST and ALT > 5x ULN, Renal glomerular filtration rate (eGFR) < 30 ml/min.
  4. PT INR>1.5ULN or APTT> 1.5 ULN, Serum amylase or lipase > 1ULN.
  5. Patients with active infection of the human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV), if patients with HBV infection with HBsAg or hepatitis B core antibody (HBcAb) positive] but HBV DNA negative can be included, However, these patients need continuous antiviral treatment and HBV DNA PCR detection every cycle after enrollment.
  6. Patients with CMV infection (IgM positive or CMV DNA was positive by PCR.)
  7. Meet any of the following criteria related to visceral function: all kinds of clinically significant abnormal rhythm or conduction need clinical pre-diagnosis Hereditary QT interval syndrome or QTcF>480 msec or taking drugs that may cause Qt interval delay or torsade de pointes. A variety of clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, and coronary artery bypass grafting in the first 6 months of the group, with New York's cardiology (NYHA) classification of grade 3 or above. Left ventricular ejection fraction (LVEF )<40%, or uncontrolled blood pressure controlled by drugs (Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mgHg).
  8. Have a history of stroke or intracranial hemorrhage within 6 months before drug administration for the first time.
  9. Major surgery was performed within 4 weeks before enrollment.
  10. Any PI3K inhibitor has been used before and the disease has progressed during the treatment period (within 6 months after the last use).
  11. Received systemic anti-tumor therapy or radiotherapy within 4 weeks before enrollment.
  12. The last time you participated in clinical trials of other drugs before enrollment was less than 2 weeks or the last time you used small molecular drugs (such as antibody drugs) was less than 4 weeks.
  13. The patients received the transplantation of somatic hematopoietic stem cells within 3 months before enrollment.
  14. Patients received allogeneic hematopoietic stem cell transplantation or had any active graft-versus-host disease within 6 months before drug administration.
  15. Take a strong inducer or inhibitor of cytochrome P4503A4 (CYP3A4) within 2 weeks before the first drug administration (3 weeks for Hypericum perforatum)
  16. Before the first drug administration, the toxic reaction of previous anti-tumor therapy has not recovered to ≤1 level (except alopecia).
  17. Patients with uncontrolled systemic infection requiring intravenous antibiotic treatment.
  18. Currently suffering from other primary tumors that need active treatment according to the guidelines.
  19. Inability to take drugs orally, previous surgical history, or serious gastrointestinal diseases such as dysphagia and active gastric ulcer may affect the absorption of drugs.
  20. Pregnant (serum pregnancy test results are positive) or lactating women
  21. Any other diseases, abnormal metabolism, abnormal physical examination, or abnormal laboratory examination with significant clinical significance, according to the researcher's judgment, it is reasonable to suspect that the patient has a certain disease or state that is not suitable for using these two drugs, or it will affect the interpretation of the research results or put the patient in a high-risk situation.

引自 ClinicalTrials.gov, NCT06158386, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06158386,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06158386